CAS: 371-15-3; 4-Fluorothioanisole

上下游产品

CAS号104-95-0 4-溴硫代苯甲醚 | CAS号352-34-1 4-氟碘苯 | CAS号67-68-5 二甲基亚砜 | CAS号624-92-0 二甲基二硫醚 | CAS号371-40-4 4-氟苯胺 | CAS号371-42-6 4-氟苯硫酚 | CAS号77-78-1 硫酸二甲酯 | CAS号658-14-0 1-氟-4-(甲基亚磺酰基)苯 | CAS号74-88-4 碘甲烷 | CAS号332-51-4 2-[(4-氟苯基)硫代]乙酸 | CAS号455-15-2 4-氟苯基甲基砜 | CAS号658-14-0 1-氟-4-(甲基亚磺酰基)苯 | CAS号175911-67-8 Benzene, 1-fluo... | CAS号405-31-2 1,2-双(4-氟苯基)二硫 | CAS号330-85-8 4-氟二苯硫醚 | CAS号940-76-1 1-氟-4-(三氟甲基硫代)苯 | CAS号453-72-5 2-氟-5-甲基磺酰硝基苯 | CAS号445-29-4 邻氟苯甲酸 | CAS号1193-82-4 苯亚砜甲酯 | CAS号19813-76-4 1-methylsulfany...

对氟苯甲砜置于三乙基硅烷,三(五氟苯基)硼烷体系中,用 Neat (No Solvent) 作为反应溶剂,化学反应 8.0H,以11%的收率获得产物4-氟茴香硫醚
参考文献:氢硅烷的b(c6F5)3-催化亚砜和砜还原为硫化物
标题:氢硅烷的b(c6F5)3-催化亚砜和砜还原为硫化物
摘要:摘要 示出了b(c 6 F 5)3以et 3 Sih作为化学计量的氢化物源催化亚砜和砜脱氧成相应的硫化物.尽管该方法在官能团耐受性方面受到限制,但是它适用于还原烷基/芳基-,芳基/芳基-和烷基/烷基取代的亚砜,包括苄基/苄基取代的衍生物.相同的协议将烷基/芳基取代的砜而不是芳基/芳基取代的砜转化为硫化物. 示出了b(c 6 F 5)3以et 3 Sih作为化学计量的氢化物源催化亚砜和砜脱氧成相应的硫化物.尽管该方法在官能团耐受性方面受到限制,但是它适用于还原烷基/芳基-,芳基/芳基-和烷基/烷基取代的亚砜,包括苄基/苄基取代的衍生物.相同的协议将烷基/芳基取代的砜而不是芳基/芳基取代的砜转化为硫化物.
DOI:10.1055/s-0036-1588476

专利信息

专利号:US-2022401561-A1
优先权日:2019-09-30
标题 :Protein-macromolecule conjugates and methods of use thereof
发明人：SONG YUNTAO; LI HUI; ZHOU HAIPING; LIAO CHUAN
权利人:BEIJING XUANYI PHARMASCIENCES CO LTD
摘要:The present disclosure provides protein-macromolecule conjugates, releasable linkers, and macromolecules, as defined herein. The disclosed conjugates provide unique properties that ae based at least upon the properties of linker and number of linker-Macromolecule moieties. Also provided herein are a method of synthesis and use of conjugates in treating diseases and disorders.

专利号:US-5721255-A
优先权日:1992-08-19
标 题 :Substituted benzylamino nitrogen containing non-aromatic heterocycles
发明人：HOWARD HARRY R; NAKANE MASAMI; IKUNAKA MASAYA; SATAKE KUNIO; ROSEN TERRY J; LOWE III JOHN A; O'NEILL BRIAN T; ITO FUMITAKA
权利人:PFIZER
摘要:The present invention relates to novel substituted benzylamino nitrogen containing non-aromatic heterocycles and, specifically, to compounds of the formula ##STR1## wherein W, R 1 , R 2 , R 3 and A are as defined in the specification, and to intermediates used in the synthesis of such compounds. The novel compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.